Oxaliplatin News and Research

RSS
Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Researchers discover enzyme crucial for DNA repair

Researchers discover enzyme crucial for DNA repair

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Hospira second-quarter 2010 net sales increase 1.2% to $968 million

Sun Pharma reports first-quarter fiscal 2011 results

Sun Pharma reports first-quarter fiscal 2011 results

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Teva second-quarter net sales increase 12% to $3.8 billion

Teva second-quarter net sales increase 12% to $3.8 billion

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

EMEND indication helps women prevent CINV

EMEND indication helps women prevent CINV

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

Hospira reports net sales of $1.0 billion for first-quarter 2010

Hospira reports net sales of $1.0 billion for first-quarter 2010

Researchers use genistein to improve outlook of pancreatic cancer

Researchers use genistein to improve outlook of pancreatic cancer